Syros Pharmaceuticals Future Growth
How is Syros Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
40.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 56 | -109 | N/A | N/A | 4 |
12/31/2024 | 14 | -142 | N/A | N/A | 4 |
12/31/2023 | 17 | -129 | N/A | N/A | 6 |
9/30/2022 | 23 | -114 | -116 | -115 | N/A |
6/30/2022 | 25 | -109 | -108 | -107 | N/A |
3/31/2022 | 24 | -97 | -109 | -108 | N/A |
12/31/2021 | 23 | -87 | -101 | -100 | N/A |
9/30/2021 | 21 | -93 | -108 | -106 | N/A |
6/30/2021 | 20 | -86 | -95 | -94 | N/A |
3/31/2021 | 18 | -81 | -81 | -80 | N/A |
12/31/2020 | 15 | -84 | -61 | -57 | N/A |
9/30/2020 | 10 | -74 | -50 | -38 | N/A |
6/30/2020 | 7 | -74 | -48 | -34 | N/A |
3/31/2020 | 4 | -76 | -54 | -40 | N/A |
12/31/2019 | 2 | -75 | -73 | -60 | N/A |
9/30/2019 | 2 | -74 | -68 | -63 | N/A |
6/30/2019 | 2 | -70 | -65 | -62 | N/A |
3/31/2019 | 2 | -64 | -60 | -58 | N/A |
12/31/2018 | 2 | -62 | -42 | -40 | N/A |
9/30/2018 | 1 | -60 | -38 | -37 | N/A |
6/30/2018 | 1 | -58 | -37 | -37 | N/A |
3/31/2018 | 0 | -57 | -35 | -34 | N/A |
12/31/2017 | 1 | -54 | -46 | -45 | N/A |
9/30/2017 | 1 | -50 | -45 | -44 | N/A |
6/30/2017 | 1 | -50 | -45 | -43 | N/A |
3/31/2017 | 1 | -51 | -44 | -43 | N/A |
12/31/2016 | 0 | -51 | -43 | -41 | N/A |
9/30/2016 | N/A | -52 | -41 | -39 | N/A |
6/30/2016 | N/A | -48 | N/A | -35 | N/A |
3/31/2016 | 0 | -41 | N/A | -30 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SYRS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SYRS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SYRS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SYRS's revenue (63.2% per year) is forecast to grow faster than the US market (7.1% per year).
High Growth Revenue: SYRS's revenue (63.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SYRS's Return on Equity is forecast to be high in 3 years time